Preventive trial of Homoeopathic medicines in COVID-19

Prophylactic effects of homoeopathic medicines in Kolkata during COVID-19 pandemic: A community-based, randomized trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/11/029265

Enrollment

20000

Registered

2020-11-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Bryonia alba 30CH

6 doses once daily for 6 days (for adults) or 3 doses for 3 days (for infants/children)

plus ascorbic acid tablets of 500 mg per day for 6 days for participants aged 5-75 years: Bryonia alba 30CH (preserved in 90% v/v ethanol)

3 (for children) or 6 (for adults) doses once daily in morning for 3 or 6 days. Each dose shall consist of either 2 (for infants/children) or 4 (for adults) medicated globules (no. 30) of cane sugar,

plus ascorbic acid tablets of 500 mg per day for 6 days for participants aged 5-75 years: Gelsemium sempervirens 30CH (preserved in 90% v/v ethanol)

3 (for children) or 6 (for adults) doses once daily in mornin

Eligibility

Inclusion criteria

Inclusion criteria: a) Persons residing in the Tangra area of Kolkata b) Age between 1 yr and 75 yrs c) Participants of either sex d) Written consent to participate (guardianâ??s consent in cases of minors)

Exclusion criteria

Exclusion criteria: a) Diagnosed or suspected cases of COVID-19 b) Currently suffering from flu-like illnesses c) People who have already taken homoeoprophylaxis in some forms within last 30 days d) Cases with vital organ failure e) Immune compromised state

Design outcomes

Primary

Measure	Time frame
Occurrence of newly diagnosed (laboratory confirmed by PCR) COVID-19 infection rates across the groupsTimepoint: Up to 30 days after completing the recommended dosage or once the person reports COVID-19 positive by PCR tests, whichever is earlier	—

Secondary

Measure	Time frame
Occurrence of flu-like illnesses and/or clinically suspected cases of COVID-19 infections across the groupsTimepoint: Up to 30 days after completing the recommended dosage or once the person reports COVID-19 positive by PCR tests, whichever is earlier	—

Countries

India

Contacts

Public ContactProf Dr Satadal Das

D N De Homoeopathic Medical College and Hospital, Govt. of West Bengal

ganguly.subhasish@rediffmail.com8017272982

Outcome results